Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sivelestat · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Sivelestat | DRUG | - |
Inclusion Criteria * show evidence of acute lung injury * be on mechanical ventilation Exclusion Criteria * have undergone certain organ transplants * have severe underlying medical problems * be unlikely to survive * be pregnant or breast-feeding
Sivelestat is an investigational small molecule being studied for use in adult respiratory distress syndrome and acute lung injury. It is a respiratory therapeutic area drug that was evaluated in a clinical trial for these conditions. The drug is still in clinical development and is not approved for commercial use.
Sivelestat is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company conducted a clinical trial to evaluate the drug's efficacy and safety in patients with acute lung injury.
Sivelestat is in Phase 1 clinical development. It has completed one clinical trial, which was a randomized, double-blind study. The drug remains investigational and has not been approved by regulatory authorities for any use.
Sivelestat was studied in a completed clinical trial registered as NCT00036062, titled "A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury." The trial enrolled 600 participants and was conducted in the United States, Australia, Belgium, Canada, New Zealand, and Spain.
Sivelestat is a distinct small molecule drug developed by Eli Lilly and Company. It is not known to be the same as any other marketed drug. Its development has focused on treating adult respiratory distress syndrome and acute lung injury.